Company Description
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer.
It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.
The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
| Country | United States |
| Founded | 2011 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Brian F. Sullivan |
Contact Details
Address: 16305 36th Avenue N, Suite 100 Minneapolis, Minnesota 55446 United States | |
| Phone | 763-392-0767 |
| Website | celcuity.com |
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary and Director |
| Vicky Hahne | Chief Financial Officer |
| Dr. John R. MacDonald Dabt, Ph., Ph.D. | Senior Vice President of Research & Development |
| Sheri Smith | Acting Head of Clinical Operations |
| Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Eldon C. Mayer III, M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | D/A | Filing |
| Apr 24, 2024 | 144 | Filing |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | ARS | Filing |
| Mar 28, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |